Coreg
Product Images NDC 68151-5048

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Coreg (NDC 68151-5048). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Carilion Materials Management, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carvedilol Phosphate Chemical Structure (Coreg Cr Spl Graphic 01)

Chemical structure of carvedilol phosphate monohydrate, the active ingredient in COREG CR. The structure includes the molecular components and hydration state indicated by H3PO4 and water molecules.*

FDA Label Image

Figure 1. Survival Analysis For Copernicus (intent-to-treat) (Coreg Cr Spl Graphic 02)

A line graph depicting % mortality over a 21 month period comparing Carvedilol to placebo. The graph shows lower mortality percentages for Carvedilol compared to placebo across the months, with a statistical significance indicated by P = 0.0014.*

FDA Label Image

Figure 2. Effects On Mortality For Subgroups In Copernicus (Coreg Cr Spl Graphic 03)

A forest plot chart showing hazard ratios for various patient subgroups including men, women, age groups (<65 and ≥65), race (non-black, black), diabetic status, ischemic vs nonischemic condition, heart rate categories (≥70 and <70), systolic blood pressure categories (≥120 and <120 mm Hg), and use of spironolactone. Each subgroup has a plotted hazard ratio with confidence intervals along a horizontal axis ranging approximately from 0.0 to 2.0.*

FDA Label Image

Figure 3. Survival Analysis For Capricorn (intent-to-treat) (Coreg Cr Spl Graphic 04)

A line graph comparing percent mortality over 24 months between placebo and carvedilol groups. The x-axis represents months, and the y-axis shows percent mortality. The graph indicates lower mortality in the carvedilol group compared to placebo, with a P value of 0.03.*

FDA Label Image

Figure 4. Effects On Mortality For Subgroups In Capricorn (Coreg Cr Spl Graphic 05)

A forest plot depicting hazard ratios with confidence intervals across various patient subgroups such as age, sex, randomization timing post-myocardial infarction, prior medication use, Killip class, thrombolytic therapy, PTCA use, heart failure status, diuretic use, angina, hypertension, diabetes, and heart rate. The plot shows the comparative hazard ratios for each subgroup in relation to an outcome, with a reference line at 1.0.*

FDA Label Image

Figure 5. Changes From Baseline In Systolic Blood Pressure And Diastolic Blood Pressure Measured By 24-hour Abpm (Coreg Cr Spl Graphic 06)

A two-part line graph showing changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP) over 24 hours after a morning dose of COREG CR at strengths of 20 mg, 40 mg, and 80 mg. The x-axis represents time in hours, and the y-axis represents blood pressure changes in mmHg. Lines are smoothed using locally weighted regression methodology.*

FDA Label Image

Label Image (Lbl681515048)

The label for COREG CR 10 mg extended-release capsules contains carvedilol phosphate as the active ingredient. It displays manufacturing details including the manufacturer GSK, lot number 4ZP2824, and expiration date 10/14. The label also indicates the package is prescription only and includes a barcode with NDC 68151-5048.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.